Abstract | Human aromatase deficiency is a very rare syndrome characterized by congenital estrogen deprivation that is caused by loss-of-function mutations in CYP19A1, which encodes aromatase. Here, we review the presentation, diagnosis and treatment of aromatase deficiency in men to provide useful advice for clinical management of the condition. At presentation, all men with aromatase deficiency have tall stature, delayed bone maturation, osteopenia or osteoporosis and eunuchoid skeletal proportions. Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1. Transdermal estradiol treatment at a daily dose of about 25 μg might be adequate for lifelong replacement therapy. BMD and levels of serum estradiol, luteinizing hormone and testosterone should be monitored carefully and considered powerful biochemical markers of adequate estrogen substitution in clinical practice. Early diagnosis is important to initiate estrogen therapy as soon after puberty as possible to avoid the skeletal complications that are associated with this condition.
Introduction
Human aromatase deficiency is a very rare syndrome that is caused by naturally occurring loss-of-function mutations in CYP19A1, which encodes aromatase. these mutations lead to abnormal protein products that result in the dysfunction of the aromatase enzyme and, consequently, in a complete lack of estrogen synthesis. 1, 2 the condition can be diagnosed at birth, which enables clinical management to begin in infancy, 3, 4 but the syndrome often remains undiagnosed until adulthood. 5−12 the discovery of loss-of-function mutations in CYP19A1 and in the gene that encodes estrogen receptor α, 13 all of which mutations result in congenital estrogen deficiency in men, as well as the study of similar knock-out animal models have improved our knowledge of the patho physiological role of estrogen in men.
1,2,14 the understanding of the role of estrogen in men has a fascinating and rather long history, 15 but the detailed characterization of the role of estrogen in men has challenged long-held views.
1,2,5,6,13 until now, however, studies in this field have mainly focused on the role of estrogen in men's health 14 and pathophysiology, 1, 2, 12, 15 whereas the clinical aspects of aromatase deficiency in men have not been studied extensively and have been only rarely reviewed. 16 to provide useful clinical advice, we approach the clinical aspects of aromatase deficiency in men in a systematic way, on the basis of both our own extensive clinical experi ence with this rare syndrome 6,9−11 and data reported by other groups.
Clinical presentation
Clinical manifestations of aromatase deficiency (Box 1) are believed to occur at puberty-mainly during late adolescence-when the effects of estrogen deprivation on bone become evident (Box 2). symptoms include a continuous, linear increase in the patient's height (as is normally observed in prepubertal children) during puberty instead of a pubertal growth spurt, the absence of the expected growth arrest, and the development of eunuchoid proportions of the skeleton, namely that the appendicular skeleton (the arms and legs) becomes longer than the axial skeleton (Box 1).
1,2,17−19 the absence of a pubertal growth spurt in men with aromatase deficiency has not been characterized appropriately, [5] [6] [7] 9, 10 never theless, the lack of a pubertal growth spurt before initiation of estradiol replacement treatment at the age of 17 years in a child whose aromatase deficiency was diagnosed early strongly supports this hypothesis. 4 the major symptoms that usually induce adult patients to seek medical consultation are continued linear growth, 6 ,9−11 widespread pain in the bones 6,9−11 and incidental discovery of unfused epiphyses during radio logical examination. 6, 7, 11 only one patient is known to have consulted a physician for infertility (Box 1). 6 at presentation, all seven men with aromatase deficiency who are described in the literature had tall stature, delayed bone maturation, osteopenia or osteoporosis, eunuchoid skeletal proportions, bone pain and progressive genu valgum (Box 1). 12, 20 several other features can be associated with aromatase deficiency, 12, 20 including the impairment of spermatogenesis, which might be mild or severe. abnormal spermatogenesis, as detected by testis biopsy in several affected adult men. 1, 6, 10, 15 Diagnosis general aspects aromatase deficiency has few symptoms during childhood and/or adolescence (Box 2) and is characterized by a slow progression during adulthood; therefore, the condition usually remains overlooked until adulthood, 20 which often results in a delayed diagnosis (Box 2). 5−11 except for one case in which aromatase deficiency was diagnosed during childhood, 4 the mean age at diagnosis for the men reported in the literature is 27.8 ± 4.7 years. [5] [6] [7] [8] [9] [10] [11] the only man reported to have estrogen resistance was diagnosed with the condition at the age of 28 years. 13 By contrast, aromatase deficiency in women manifests at birth (as ambiguous genitalia) 21, 22 or at puberty (as primary amenorrhea) 23 and can, therefore, be diagnosed in childhood. the condition should be suspected in newborn boys if the mother exhibits signs of progres sive virilization during the third trimester of pregnancy 1, 2, 20 and in adolescents if a pubertal growth spurt is absent (Box 2).
1,2 nevertheless, the absence of a dramatic increase in growth rate at puberty, eunuchoid proportions of the skeleton and delayed bone maturation are very difficult to detect at the early stage of aromatase deficiency, and, thus, the syndrome is unlikely to be suspected before adulthood (Box 1).
Progressive virilization of the mother (charac terized by severe acne, lowering of voice, hypertrophy of the clitoris, frontal balding and facial masculinization) during pregnancy has been reported in most cases of male aromatase deficiency; 3, 5, 7, 8 when the fetus with aroma tase deficiency is female, the mother always presents with this condition. 1, 2, 12, [20] [21] [22] [23] maternal virilization during pregnancy 24 is very rare and might be related to conditions other than aromatase deficiency, such as luteoma or other steroidproducing ovarian tumors, 25 cytochrome P450 oxidoreductase deficiency (PorD) 26, 27 or poly cystic ovary syndrome. 25 the underlying mechanisms that lead to the mother's virilization during pregnancy in the case of aromatase deficiency include dysfunction of the placental aromatase and the consequent lack of conversion of androgens into estradiol within the placenta, which results in an excess of androgens in the mother's circulation. this mechanism explains why virilization resolves after the baby is born.
1,2,5 in cases for which no medical history is available, we do not know whether the patient's mother experienced virilization. 6, [9] [10] [11] Besides the mother's virilization during the last trimester of pregnancy, however, the only reason to suspect aromatase deficiency in a newborn boy is diagnosis of the syndrome in a relative (usually a sibling; Box 2). 3, 4 clinical diagnosis the appropriate path to confirm or reject the clinical diagnosis of aromatase deficiency and to select candidates for genetic analysis should be based on data obtained from Medical history and physical examination a suspected diagnosis might be reinforced by information about the family history of the patient, such as the occurrence of the above-mentioned virilization of the mother. three of the eight men with aromatase deficiency who are described in the literature were born from consanguineous parents 3, 4, 6, 7 (as are most women with aromatase deficiency). 20 ,23 a family history was unavailable for two of the men, 9, 10 and no consanguinous relationships were known in the remaining three cases. 5, 8, 11 Both parents' heights are neces sary to calculate the patient's target height and to ascertain the presence of abnormally tall stature. 5 the health status of the patient's siblings should also be investigated, with particular attention paid to a history of ambiguous genitalia and/or delayed puberty in sisters. 2, 5 a detailed interview should collect all available data on the patient's growth from birth to adulthood and on pubertal development and onset.
1,2,19 a history of cryptorchidism needs to be investigated as abnormalities in the descent of testes have been described in three patients. 8, 9, 11 Physicians should also ask about the patient's reproductive status, as sex steroids can influence both spermatogenesis and sexual behavior. 1, 2, 15 During physical examination, physicians should look for all the signs that are summarized in Box 1, including those that present only occasionally, such as skeletal deformities 7 or increased testicular volume. 5, 7 in particular, the recognition of signs of metabolic diseases, 1,2,5,7,9,10,12,20 such as insulin resistance, will enable the physician to conduct the appropriate biochemical analyses.
Differential diagnoses aromatase deficiency should be strongly suspected in adult men with continued linear growth, height increases in adulthood and/or documented unfused epiphyses. the flow chart in Figure 1 was devised to help physicians in diagnostic decision-making. a first step in the clinical investigation of aromatase deficiency in adult men should include measurements of serum estradiol, testo sterone, luteinizing hormone (lH) and follicle-stimulating hormone (FsH) levels and a standard radio graphy of the hand and wrist to characterize the patient's hormonal pattern and identify the presence and degree of the delay in bone maturation. 16 the measurement of serum levels of sex steroids and gonadotropins can help to differentiate aromatase deficiency in men from other clinical conditions (table 1) . estrogen resistance, a condition with the same clinical features as aromatase deficiency, is easy to diagnose as it is characterized by higher than normal serum estra diol levels (table 1, Figure 1) . 13 26, 27 are characterized by numerous clinical symptoms of various severity, including hormonal abnormalities owing to dysfunction of more than one step in the steroidogenesis pathways. 26, 27 Classic, isolated aromatase deficiency is characterized by the above-described dysfunction of the aromatase enzyme.
1,2 the absence of specific symptoms, including greatly elevated serum adrenal androgen levels, hypertension, abnormal levels of serum electrolytes and ambiguous genitalia, rules out combined 17α-hydroxylase-17,20-lyase deficiency and isolated 17,20-lyase deficiency.
28,29 the absence of adrenal dysfunction, evident abnormalities in skeletal development (for example, brachycephaly or arachnodactyly) and of disorders of sexual development rules out PorD, 26, 27 whereas the occurrence of normal virilization at puberty together with normal to high serum testo sterone level rules out hypogonadism 30, 31 as possible causes of delayed bone maturation in men with aromatase deficiency (table 1, Figure 1 ). REVIEws radiography of the hand and wrist is a simple, quick and inexpensive procedure for verifying the completion of bone maturation (indicated by fused epi physes) in adult men; the initial thinning and eventual disappearance of the growth plate substantiates the cessation of growth. 33 in cases of incomplete bone maturation (indicated by unfused epiphyses), radio graphy can be used to measure in detail the bone age by the Greulich and Pyle method 34 or the tanner and whitehouse method, 35 both of which are widely used in clinical practice. radiography of the hand and wrist showed a pattern of unfused epiphyses in all the adult men with aromatase deficiency described in the literature.
1,2,5-12 as unfused epiphyses also are present in patients with estrogen resistance, 13 combined 17α-hydroxylase-17,20-lyase deficiency, isolated 17,20-lyase deficiency, 28 PorD 26, 27 and severe, prepubertal male hypogonadism, 30,31 radiography alone, without evaluation of hormone levels, cannot confirm the diagnosis.
the main limitation of the commercially available assays for the detection of serum estradiol is their poor accuracy within the normal range for men. 32, 36 at present, the gold standard tests for the measurement of very low levels of serum estradiol are gas chromato graphy and tandem mass spectrometry. 37 the commercially available kits that have satisfactory sensitivity and speci ficity (such as third-generation radio immunoassays) [9] [10] [11] 38 provide useful information for clinicians, especially in the context of all other hormones of the hypothalamic−pituitary−gonadal axis.
32,39 the findings of undetectable estradiol levels, unfused epiphyses and normal or elevated levels of both gonadotropins and testosterone, together with most of the signs and symptoms listed in Boxes 1 and 2 might be sufficient for a clinical diagnosis of aromatase deficiency in an adult man (Figure 1 ). 16 Genetic analysis after the first 3−6 months after birth, a clinical diagnosis of aromatase deficiency cannot be postulated on the basis of circulating hormone levels in infants and pre pubertal boys 3, 4 owing to the low secretion of sex steroids at those ages. thus, when aromatase deficiency is suspected in a boy before puberty, genetic analysis is essential to make the diagnosis (Figure 1 ). analysis of CYP19A1 can reveal point mutations and/or base pair deletions. aromatase deficiency is rare; therefore, the reli ability of a diag nosis that is based solely on clinical data (including signs, symptoms and hormonal and bone-related outcomes) is poor, especially when the limitations of estradiol assays are considered. 36, 37 thus, to confirm the diag nosis in adults, genetic testing should be performed, even if the clinical diagnosis has been made ( Figure 1) . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 20 a genetic diagnosis can help to distinguish aromatase deficiency from other rare conditions that are characterized by sex steroid deficiency and involve abnormal estrogen secretion (such as PorD), 26, 27 especially when the hormonal assay results do not fully clarify the endocrine pattern of the disease and the clinical charac teristics partly overlap with those of other conditions. in a well-equipped, standard molecular biology laboratory, sequencing of CYP19A1 is easy to perform, reproducible and hardly constitutes an insurmountable obstacle. a thorough characterization of the patient's genetic pedigree also requires gene sequencing of the patient's parents and siblings. [5] [6] [7] 20, 22, 23 a standard karyotyping analysis might rule out major chromosomal diseases, especially Klinefelter syndrome, which shares some clinical features (such as tall stature and eunuchoidism) with aromatase deficiency (Figure 1 ).
Diagnosis of related disorders
several metabolic, bone and reproductive abnormalities have been repeatedly described in men with aroma tase deficiency.
1−12 the second step in the clinical management of a man with suspected aromatase deficiency should include a radiological and a detailed biochemical study (Figure 1 ), both of which are useful for identifying ancillary disorders that are commonly associated with the condition (Boxes 1 and 2) . 12 Biochemical analyses should focus on the lipid profile, liver function and levels of fasting glucose and insulin to evaluate the degree of biochemical abnormalities that are related to the metabolic syndrome. 9, 10, 12, 20, 40, 41 although the homeostasis model assessment (Homa) index 42 is not widely used yet in clinical practice, this method can help to determine the degree of insulin resistance in patients with aromatase deficiency (Figure 1) . 9, 10, 12, 20, 40, 41 liver ultrasonography might be useful in investigating liver morphology and diagnosing fatty liver disease, 43 which is often related to estrogen deficiency in men.
9−11,44 a full assessment of reproductive functions, which are often impaired in men with aromatase deficiency, 1,2,5−11,15 is also recommended and should include hormonal and sperm analysis. Baseline bone status 16, 38 can be assessed by measuring the levels of the biochemical markers of bone turnover and by measuring BmD at the lumbar Figure 1 ) by dual-energy X-ray absorptiometry (DeXa), the gold standard method. 32 a third clinical investigative step (which is particularly important in the prepubertal period) might include assessment of pituitary function, which can be impaired in men with aromatase deficiency. 7, 11, 12, 46 if signs of insulin resistance are present or the preliminary results show hyperinsulinism or a higher than normal fasting glucose level, 8, 9, 11, 40 a clinical assessment of glucose metabolism by a standard oral glucose tolerance test is required. 47 Treatment estrogen replacement therapy should be started as soon as the clinical diagnosis of aromatase deficiency has been reached in an adult man; the genetic diagnosis provides further information that is useful to choose appro priate treatment. the treatment approach should take into account the known effects of estrogen in men. the effects of estrogen on growth and the growth plate are biphasic: low amounts of estrogen increase the cartilage growth rate and consequently the patient's height, whereas high amounts of estrogen induce growth arrest, 48−50 probably by promoting chondrocyte apoptosis within the epiphyseal cartilage 51 and the subsequent mineralization of the cartilage.
12,17−19 a prompt start of treatment ensures rapid completion of bone maturation 6, 7, 10, 45 and, hence, prevents a further increase in height and a worsening of the eunuchoid body habitus;
18,52 the latter two events are well documented in a case where estradiol treatment was started at a late phase 9 and in a case where the patient was undertreated.
11
Short-term or medium-term estrogen treatment High doses of estrogen in adult men with aromatase deficiency leads to a rapid completion of skeletal maturation within 6-9 months. 12 ‡ Parameters useful to monitor the effects of treatment on associated diseases that are often related to aromatase deficiency, such as diabetes mellitus, dyslipidemia, and fatty liver disease. Radiography is useful only during short or medium-term follow up and should not be performed after epiphyseal closure is attained.
§ Parameters that are useful to monitor at short-term and mid-term follow-ups. Abbreviations: , slightly increased; , increased; , slightly decreased; , decreased; =, normal; DEXA, dual-energy X-ray absorptiometry; DHEAs, dehydroepiandrosterone sulfate; E2, estradiol levels; FsH, follicle-stimulating hormone levels; IGF-I, insulin-like growth factor I; LH, luteinizing hormone levels; sHBG, sex hormone-binding globulin; T, testosterone levels.
REVIEws estradiol daily) that is sufficient to keep serum estradiol levels between the highest quartile (about 40 pg/ml) of the normal range and slightly above the upper limit of normal 6, 7, 9, 16, 45 has the same effects as those observed in boys in the final phase of puberty. During this phase, serum estradiol levels are higher than those in early puberty 53 and induce the completion of bone maturation 19,50 within 6−9 months 1,38,45 through rapid bone elongation and an increase in height followed by quick epiphyseal closure and growth arrest. 1, 6, 7, 9, 11, 45 the second main goal of estrogen therapy is normalization of BmD. this process should mimic peak bone mass acquisition that would have otherwise been completed at the end of puberty. 32, 54, 55 estrogen treatment increases BmD and restores normal values within 6−9 months in men with aromatase deficiency. 7, 9, 11, 38, 45 Prolonged therapy might be required, especially at the femoral site, 56 if a low starting dose of estrogen was used. 11, 54 a daily dose of transdermal estradiol ranging from 25 μg to 50 μg is usually adequate for maintaining normal to high levels of serum estradiol and for the rapid co mpletion of bone maturation and mineralization. 12, 17 long-term estrogen treatment once epiphyseal closure, bone maturation and bone mineraliza tion have been achieved, estrogen treatment should be continued as a lifelong replacement therapy, the main goal of which is to prevent bone loss and reduce the risk of cardiovascular diseases.
adequate amounts of exogenous estradiol prevent bone resorption, ensure the maintenance of bone mass and promote long-term bone health, 6, 7, 38, 45, 54, 56 and such treatment needs to continue to maintain the BmD value that was initially achieved. 32, 38, 54, 56 Decreased doses of estradiol result in lower than normal serum estradiol levels (as occurs in healthy, aging men), 32 ,55 a condition that leads to a reduction in BmD. 38, 56 in addition, normal androgeniza tion is necessary for the long-term maintenance of BmD. 38, 54, 56, 57 Finally, maintaining an adequate estrogen milieu helps to achieve optimal cortical mineraliza tion in men, 4, 54, 57 probably because the hormone exerts a priming effect on bone cells and acts as a permissive factor for the anabolic action of androgens. 54 in addition to improving bone health, estrogen replace ment therapy can improve other clinical features and/or biochemical abnormalities of adult patients with aroma tase deficiency, 6, 7, 11, 45, 56 especially in those who have symptoms related to the metabolic syndrome, 10, 47 such as impaired insulin sensitivity, 5,7,9,10,45 glucose in tolerance or diabetes mellitus, 8,9 dyslipidemia 5−11 and visceral adiposity. [5] [6] [7] [8] [9] [10] [11] 56 a daily dose of transdermal estradiol of about 25 μg is usually adequate for maintaining serum estradiol within the normal range for adult men in the long term. 12 effectiveness of estrogen treatment estrogen treatment in men with aromatase deficiency is effective at normalizing gonadotropin secretion, 6, 7, 9, 38, 45, 46, 56 lowering circulating lipid levels 6, 7, 9, 45, 56 and improving glucose metabolism, 6, 7, 56 insulin sensitivity 6, 9, 40, 45 and liver function 9 (Box 3). these positive effects of estrogen treatment mostly lead to an improved metabolic outcome and a reasonable reduction of cardiovascular risk. men with aromatase deficiency are often reluctant to use 'female' hormones, so their adherence to estrogen treatment might be poor. this behavior is documented in a striking case 11 and occurred to a lesser extent in three patients who were managed by our group (personal observation).
6,9,10 the patient's expectations should, therefore, be managed by providing adequate information on what the expected results are and which goals are not achievable, to improve the patient's compliance with therapy (Box 3). some disorders that are associated with aromatase deficiency, such as impaired spermatogenesis, abnormal fat distribution, adiposity and skeletal abnormalities (such as kyphosis or eunuchoid skeleton), are in fact not modifiable by and do not benefit from estrogen replacement therapy that is started in adulthood. 6, 7, 9, 11, 12, 15, 45, 54, 58 Physicians should inform adult patients about aromatase-deficiency-related, irrever sible clinical conditions that do not benefit from estrogen treatment, the most important of which is infertility.
Timing of estrogen treatment the fact that estrogen replacement therapy is often started in adulthood is usually attributable to a delay in diagnosis (Boxes 1 and 2).
5−11,45 such a delay means that some abnormalities (Box 3) that arise from the prolonged course of the unrecognized syndrome cannot be corrected.
the ideal timing for starting estrogen treatment in men with aromatase deficiency seems to be puberty, 4 but REVIEws such timing requires an early diagnosis, the difficulties of which have been discussed above (Box 2). if the diagnosis is made at birth or during infancy, low doses of exogenous estradiol (0.8−0.12 μg/kg daily) should be administered at the beginning of puberty 19, [48] [49] [50] and then progressively increased from about mid-puberty (16-17 years old), to mimic the continuous, gradual increases in serum estradiol level that characterize the progression of puberty in boys. 53 such treatment proved to be effective at achieving a final height within the genetically determined target for a boy with aromatase deficiency. 4 a high dose of estradiol before puberty should be avoided as it would inhibit the onset of the pubertal growth spurt. 48 although no precise age for initiation of the treatment has been established, this boy has been treated from age 17 years (that is, the final pubertal period) and has not developed the classic skeletal features of adult men with aromatase deficiency. 4 this observation suggests that an appropriate treatment timing is crucial for normal bone maturation.
Pharmaceutical formulation and safety
Conjugated estrogens, valeriate estradiol, transdermal estradiol patches and estradiol gel are all effective in men with aromatase deficiency. the dosage depends on the type of formulation and the route of administration. most of the available data involve transdermal patches, 6,7,9,11,38,56 so comparisons can be made between the various transdermal dosages that have been used in different settings.
6,7,9,11,38,56 a formulation that contains estradiol is preferred as this molecule is easy to detect in serum samples. on the other hand, ethinylestradiol is probably also effective but is difficult to detect in serum. Conjugated estrogens 45 and estradiol valeriate 4 are valid alternatives. the use of selective estrogen receptor modulators can also be regarded as a possible, second-choice alternative to estradiol treatment, but only in particular circumstances; preliminary results on the effect of raloxifene in a man with aromatase deficiency, in fact, are not encouraging. 59 although raloxifene is effective at increasing BmD, the drug did not promote bone maturation and growth arrest in this patient.
estradiol replacement therapy seems to be welltolerated by men with aromatase deficiency. no adverse effects have been reported, 4, [6] [7] [8] [9] [10] [11] [12] 16, 45 even when increased doses of estradiol were administered for a short period of time to bring serum estradiol levels to slightly above the normal range. 6, 12, 16, 45, 54 moreover, estradiol treatment had no detrimental effects on sexual behavior in any of the patients described in the literature; to the contrary, such treatment seemed to improve their sexual health, although evidence for such an effect is still weak. 15, 60, 61 the choice of pharmaceutical formulation depends on the physician's experience with estrogen adminis tration and on the patient's compliance with therapy and/or preferences. 16 the safety of estrogen treatment should be monitored, and the prolonged use of supraphysiological doses should be avoided, as the safety of high doses has been established only for brief periods of use. 6, 12, 16, 45, 54 counseling and additional treatments estrogen replacement therapy should be accompanied by the concomitant administration of calcium and vitamin D 6, 9, 45 in order to obtain a synergic effect on bones and prevent or cure vitamin D deficiency. 7, 56 specific counseling on healthy nutrition (such as follow ing a hypocaloric diet) and behavior (such as increased physical activity) should be offered to prevent vis ceral fat distribution and overt obesity 10 and to treat over weight and obesity that have not been modified by estrogen replacement therapy (Box 3).
9,40,56 such counseling is also useful for adequate control of glucose and lipid metabolism. 40 Patients who develop metabolic diseases, such as diabetes mellitus or severe dyslipidemia, need specific treatment.
Congenital estrogen deficiency in men, if diagnosed in adulthood, is associated with an increased risk of cardiovascular diseases. 1, 2, 12, 62, 63 Physicians should recommend lifestyle changes (such as quitting smoking and monitoring blood pressure) to such patients to help prevent the development of cardiovascular diseases.
Genu valgum [5] [6] [7] [8] [9] [10] [11] [12] 45 and other skeletal abnormalities 6, 7, 54, 56, 58 require specific treatment approaches, which might include surgical correction. the patient described by Carani and co-workers 6 underwent a surgical correc tion of valgism and hip prosthesis surgery to treat bi lateral osteonecrosis of his femoral head. 58 the co existence of these skeletal abnormalities often limits the patient's mobility and can contribute to the worsening of overweight and/or obesity as well as of osteopenia.
Follow-up
the most useful parameters for monitoring the adequacy of estrogen treatment are BmD and serum levels of estradiol, gonadotropins (especially lH) and testosterone. 12, 16, 17 the estrogen dosage can be considered optimal when all these parameters remain within the normal range. 16 in replacement therapy, an adequate dose of estrogen should maintain serum levels of estradiol above the lower quartile (>18-20 pg/ml) but within the upper limit of the normal range to ensure normal estrogenization in men. normal serum levels of estradiol are generally sufficient to keep serum lH levels within the normal range. 6, 7, 9, 11 FsH levels, on the other hand, are dependent on the fertility of the patient and often remain above the normal range during estrogen treatment if a concomitant impairment of spermatogenesis is evident. 15, 46 nevertheless, levels of serum gonadotropins and, above all, of lH do represent accurate parameters for monitoring estrogen replacement therapy, as estradiol, especially circulating estradiol, is the main regulator of gonadotropin secretion at the level of both the pituitary gland 46 and the hypothalamus. 39 testosterone levels are a good indicator of overtreatment during estrogen therapy, as the level decreases substantially when lH production is suppressed by an excessive amount of exogenous estrogen, 6, 7, 9, 12, 54 which REVIEws has inhibitory effects on both the hypothalamus and pituitary gland. 39, 64 Bone mineralization, the achievement of peak bone mass 32 and the relationship of both processes to the dosage of estrogen can be monitored by DeXa. as expected, lowering of the transdermal estradiol dose in a man with aromatase deficiency resulted in decreased BmD; 38 this finding confirms that BmD provides information on the adequacy of estradiol treatment on pr omoting and ma intaining bone health. 4, 6, 7, 9, 11, 16, 17, 20, 38, 45, 54, 56 in conclusion, BmD and serum levels of estradiol, lH and testosterone should be considered by clinicians as powerful biochemical markers for adequate estrogen substitution and reliable parameters for dose optimization. as mentioned above, an excessive amount of exogenous estrogen results in suppression of lH and in testo sterone deficiency, 6, 7, 9, 12, 54 whereas an insufficient dose can result in BmD loss. 11, 38 in clinical practice, dose adjustments are needed during long-term treatment to identify the optimal dosage that keeps all the above mentioned parameters as close as possible to the normal range for adult men to ensure bone maintenance and physiological estrogenization. 12, 16 in the short-term and mid-term, radiography of the hand and wrist can be used to monitor bone maturation. Completion of bone maturation generally occurs 6−9 months after the start of estrogen treatment, but only if the dosage is adequate. 6, 7, 9, 45 an insufficient amount of exogenous estrogen fails to induce epiphyseal closure, as reported in a patient with estrogen resistance, 65 and lengthens the time course that is needed for completing bone maturation, which may necessitate estrogen dose adjustments. 11 the possible occurrence and/or worsening of associated complications and comorbidities in adult men with aromatase deficiency can be monitored either by several biochemical parameters or by measuring the progress of certain signs, such as acanthosis nigricans, 9 height and anthropometric parameters, that are associated with adiposity (weight, waist circumference and hip circumference).
9,10 monitoring of the latter parameters, when accompanied by biochemical tests, is useful for establishing the presence and degree of all the abnormalities that are related to the metabolic syndrome; 9,10,41 in addition, these parameters are easy to evaluate at each visit. metabolic disorders, including nonalcoholic fatty liver disease, can improve, at least partially, during estrogen replacement therapy. 6, 7, 9, 11, 40, 45 the Homa index 42 provides useful information on the effects of estrogen treatment on a patient's insulin sensitivity. 40, 56 Areas of uncertainty at present, the physiological role of the very small amount of estrogen present in boys before puberty is unknown. 36, 66 serum estradiol in children and prepubertal boys is undetectable by commercially available assays. However, very low levels of circulating estradiol can be detected by ultrasensitive assays, 36, 66 as would be expected on the basis of the aromatase expression that is observed in children. 67 such expression accounts for in situ estrogen production, which has both autocrine and paracrine effects. the long-term consequences of estrogen deficiency before puberty in boys are not foreseeable. the approach that advocates initiation of estrogen treatment at puberty 4 is empirical and not based on solid evidence. thus, the necessity of estrogen treatment during childhood and its relative dosage are undetermined.
From a pathophysiological viewpoint, hardly any data are available concerning the possible occurrence and relative phenotype of nonclassic, partial aromatase deficiency in men (in contrast to the partial aromatase deficiency that has been described in women). 23, 68 Furthermore, the possible role of aromatase enzyme impairment in combined dysfunction of the enzymatic pathways of steroido genesis should be taken into account, 69 and the relative role of estro gen deficiency in the development of the clinical pheno type of impaired steroidogenesis remains to be elucidated in detail. 26, 27, 69 spermatogenesis is often impaired in adult men with aromatase deficiency, but whereas a cause-effect relationship has been established in mice, 14 such a relation ship still remains to be demonstrated in humans. 15 to date, however, none of the men with known aromatase de ficiency has generated offspring.
the real effect of estrogen treatment on sexual behavior, quality of life and well-being in adult men with aromatase deficiency remains to be determined. all evidence of a positive role of estrogen treatment in sexuality 15 and well-being can be at least partially attributed to the placebo effect or to the positive feeling about finally reaching a diagnosis and starting a specific treatment. 60, 61 the long-term outcome of estrogen treatment in terms of comorbidities and mortality is not yet known. a tendency towards precocious atherogenesis 9 and susceptibility to cardiovascular diseases is assumed to occur as a result of estrogen deprivation, 1, 2, 9, 10, 14, 62, 63, 70 but to date no major adverse cardiovascular event has been reported in men with aromatase deficiency.
Furthermore, we do not know whether the peak bone mass that can be reached during adulthood in treated patients is similar to that which should have been obtained during puberty. the delayed achievement of peak bone mass could compromise bone quality and bone strength, 32, 55 especially in patients whose skeletal growth continued during adulthood and have skeletal malformations (microdeformations and macrodeformations). 7, 54, 58 Conclusions men with aromatase deficiency need life-long estradiol replacement therapy to ensure adequate bone mineralization and good health 12, 16 and to minimize the risk of bone fracture. 32 the androgen−estrogen imbalance can impair the clinical condition of these patients, 40, 70 specifically with regard to vascular reactivity and endothelial fu nction. 62, 63 the best strategy for preventing early-onset REVIEws and late-onset manifestations of aromatase deficiency consists of an early diagnosis. Gynecologists' acquaintance with the syndrome should, therefore, be encouraged so that they can suggest screening for the syndrome at birth in all children whose mothers had signs of viriliza tion during pregnancy. when an early diagnosis is achieved, estrogen treatment should be started at the onset of puberty, although the precise age for treatment initiation has not yet been established. additional studies are needed to elucidate the full clinical spectrum of this rare syndrome and strengthen the evidence regarding the benefits and risks of estrogen replacement therapy in men with aromatase deficiency.
Review criteria
we reviewed all eight cases of men with aromatase deficiency that have been described in the literature. Four of the eight patients were described, diagnosed and clinically managed by our group. Additional data were obtained from searches on PubMed, using the keywords "aromatase deficiency" and "estrogen deficiency" and limiting the search to studies of men that were published between 1 January 1993 and 31 December 2008. The reference lists of identified articles were also searched for further papers. Except for two studies 8, 52 for which only abstracts are available, all identified papers are English-language, full-text papers.
